Results 31 to 40 of about 7,378 (198)

Use of new, once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis. Is there anything new under the sun? [PDF]

, 2009
5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine.
Lakatos, Péter László
core   +1 more source

Successful management of HIV infection in a patient with ulcerative colitis; a case report [PDF]

Journal of Preventive Epidemiology, 2021
Human immunodeficiency virus (HIV) is an infectious disease that is rarely seen in ulcerative colitis patients. Both diseases commonly involve the colon.
Zain Majid, Shoaib Ahmed Khan, Hina Ismail, Nishat Akbar, Rajesh Mandhwani, Nasir Luck   +5 more
doaj   +1 more source

Mesalamine induced side effects: clinical case presentation. [PDF]

, 2023
Introduction. Mesalamine is a drug used to treat ulcerative colitis. The frequency of adverse effects of mesalamine in patients is extremely rare. Adverse effects may include gastrointestinal disorders, headache, skin reactions, arthralgia.
Zuzo, Anastasija,
core  

Distal Ulcerative Colitis Refractory to Rectal Mesalamine: Role of Transdermal Nicotine versus Oral Mesalamine [PDF]

, 2002
BACKGROUND: Distal ulcerative colitis usually responds to treatment with rectal mesalamine, but the management of refractory cases is poorly ...
Mario Guslandi, Pier Alberto Testoni, Roberto Frego, Edi Viale   +3 more
core   +1 more source

Anti-oxidant and anti-inflammatory potential of different polymer-based mesalamine delayed-release granules in TNBS-induced ulcerative colitis in wistar rats

Saudi Pharmaceutical Journal
Ulcerative colitis (UC) is an inflammatory condition of colon characterized by severe damage to the innermost colon tissues. A number of studies described the use of medication delivery systems based on natural polymers like polysaccharides for the ...
Imtiyaz Ahmed Najar, Archana Sharma, Abdulrahman Alshammari, Thamer H. Albekairi, Metab Alharbi, Taief Ahmad Dar, Zulfkar Latief Qadrie, Atul Kabra, A.M.J Newton, Manish Kumar   +9 more
doaj   +1 more source

Ocular facial myositis and sialadenitis presenting with new onset ulcerative colitis. [PDF]

JPGN Rep
Abstract Extra‐intestinal manifestations of inflammatory bowel disease (IBD) can involve most organ systems, although the immunologic underpinnings are not well understood. Most patients who present with an extra‐intestinal manifestation have a single site of extra‐intestinal involvement; however, a small cohort presents with multiple different sites ...
Du N, Mendez N, Darbari A.
europepmc   +2 more sources

Tacrolimus Bridging and Combination Therapy Following Infliximab and JAK Inhibitor Failure in Ulcerative Colitis: A Case Series. [PDF]

JGH Open
ABSTRACT Background Calcineurin inhibitors such as tacrolimus are established rescue therapies for steroid‐refractory ulcerative colitis (UC). However, their efficacy and safety as bridging or combination therapy following failure of both anti‐tumor necrosis factor (anti‐TNF) and Janus kinase (JAK) inhibitor therapy remain uncertain.
Vootukuru N, Hilley P, Wong D, Srinivasan A, De Cruz P, Choy M.   +5 more
europepmc   +2 more sources

Design and Characterization of Mesalamine Loaded Nanoparticles for Controlled Delivery System [PDF]

Nanomedicine Research Journal, 2016
Objective(s): Nanoparticles (NPs) are known for their specific accumulation in the inflamed tissues of the colon and thus allow a selective delivery to the site of inflammation with minimum adverse effects.
Simin Seifirad, Hasan Karami, Shadab Shahsavari, Farzad Mirabasi, Farid Dorkoosh   +4 more
doaj   +1 more source

Mesalamine induced hepatotoxicity. Is mesalamine safe?

Revista Española de Enfermedades Digestivas
Mesalamine is a medication used widely in the treatment of patients with inflammatory bowel disease. Although mesalamine is considered safe, hepatotoxicity has been reported with an incidence of 0-4%. We present the clinical picture of a patient with hepatotoxicity due to mesalamine.
Javier, Pérez-Valenzuela, Lorena, Castro Solari, Rodrigo, Quera, Luis, Contreras   +3 more
openaire   +2 more sources

Growth and development in paediatric onset inflammatory bowel disease: Data analysis from the CEDATA registry

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objective Different therapies may affect the growth and development of children and adolescents with inflammatory bowel disease (IBD) supporting specific therapy algorithms for paediatric Crohn's disease (CD) and ulcerative colitis (UC). Methods Growth and development data from the German–Austrian CEDATA‐GPGE registry entered between 2004 and ...
Ilse Broekaert, Anna Schmidt, Christoph Hünseler, Jan Delaffolie, CEDATA Study Group   +4 more
wiley   +1 more source